explore -WSS

explore

author：explore 2025-09-29 18:15:53 - browse：946

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Poor hospice wound care hurts patients and families

Study fuels hope CAR

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Surge of respiratory disease in China has likely explanation

explore

explore

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Are embryos people? Reproductive medicine's future depends on the answer

Activists slam private health insurers over coverage restrictions

Redefining sustainability for the pharmaceutical industry

23andMe had bad news about my health. I wish a person had delivered it

Gain of function research would be limited under House proposal

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Affirmative action in medical school literally saved lives

NEJM study measures Covid brain fog, impact on IQ

leisure time

Gain of function research would be limited under House proposal

Laying a path for careers in science

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Wegovy, Zepbound and weight loss drugs that preserve muscle

Virtual repurposing can help discover new uses for existing drugs

hotspot

leisure time

knowledge

entertainment